ADC Therapeutics (ADCT) Operating Margin (2021 - 2026)
ADC Therapeutics (ADCT) posted Operating Margin of 121.07% for Q1 2026, up 35.78% sequentially from 188.52% in Q3 2025, and up 251.0% YoY from 34.49% in Q1 2025.
ADC Therapeutics (ADCT) Operating Margin (2021 - 2026) Analysis & Trends
ADC Therapeutics has reported Operating Margin for 6 years, with the latest figure at 121.07% in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -562.07% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 19.06% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 17.93% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -0.36% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 19.75% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -35.57% |
| 10 | ADC Therapeutics | 148.95 Mn | -70.15 Mn | 17.14 Mn | -132.03% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -132.03% |
| Mar 31, 2026 | -121.07% |
| Sep 30, 2025 | -188.52% |
| Jun 30, 2025 | -234.34% |
| Mar 31, 2025 | -123.58% |
| Sep 30, 2024 | -192.61% |
| Jun 30, 2024 | -166.81% |
| Mar 31, 2024 | -186.19% |
| Sep 30, 2023 | -249.42% |
| Jun 30, 2023 | -205.62% |
| Mar 31, 2023 | -271.55% |
| Sep 30, 2022 | -4.08% |
| Jun 30, 2022 | -401.43% |
| Mar 31, 2022 | -86.81% |
| Sep 30, 2021 | -439.58% |
| Jun 30, 2021 | -1,874.52% |